

CURRICULUM VITAE

• PERSONAL INFORMATION

Full name: Maurizio Sessa

Date of birth: 04/02/1990

Nationality: Italian

Spoken languages: Italian (mother tongue), English (fluent), Danish (intermediate)

• EDUCATION

- 2021 Universitetspædagogikum
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
- 2017 PhD in Translational Medicine
Department of Translational Medicine, University of Campania “L. Vanvitelli”, Napoli, Italy.
PhD supervisors: Prof. Francesco Rossi and Prof. Christian Torp-Pedersen
- 2017 Certified program in Regulatory Affairs
Department of Economy and Health, Donau Universität Krems, Krems, Austria
- 2014 Master in Pharmacy
Department of Translational Medicine, Second University of Naples, Napoli, Italy

• RESEARCH METRICS

Scopus Author ID: <https://www.scopus.com/authid/detail.uri?authorId=56355170100>

ORCID: <https://orcid.org/0000-0003-0874-744>;

H-index: 18 (Scopus)

Citations: 915 (Scopus)

Published articles in peer-reviewed journals with impact factor: 79

First authorships: 23

Last authorships: 15

• GROUP LEADERSHIP

Since 2020, I am leading a new research group (Drug Safety Group) at the Department of Drug Design and Pharmacology, University of Copenhagen. Currently (latest update: Tuesday, 13 June 2023), the group is composed of 1 postdoctoral researchers, 3 PhD Students, 1 Erasmus+ Trainee, and 5 master’s students.

I have received formal training in the leadership of a research group with the course entitled “Leading Research” sponsored by the Department of Drug Design and Pharmacology at the University of Copenhagen.

• CURRENT POSITION

- 2019 - Tenure Track Assistant Professor of Pharmacovigilance and Pharmacoepidemiology
ongoing Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

• PREVIOUS POSITIONS

- 2018 – 2019 Postdoctoral researcher in Pharmacovigilance and Pharmacoepidemiology
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
- 2017 - 2018 Postdoctoral researcher in Pharmacovigilance and Pharmacoepidemiology
Department of Translational Medicine, University of Campania “L. Vanvitelli”, Napoli, Italy

• SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

2018 – 2022 **Number of postdoctoral researchers:** 3
Number of PhD students: 3
Master's Students: 20
Role: Main Supervisor.
Where: Department of Drug Design and Pharmacology, University of Copenhagen, Denmark.

• TEACHING ACTIVITIES

In the period 2018-2022, I have been course coordinator and lecturer for courses at all educational levels, from bachelor to PhD at the University of Copenhagen, Atrium, University of Sorbonne, and Karolinska Institutet. Courses taught include:

- 1) Fundamentals of register-based pharmacoepidemiology: evidence synthesis, data sources, and study design (PhD course - course coordinator).
- 2) Pharmacovigilance and Pharmacoepidemiology (Elective course - course coordinator).
- 3) Register-based research in Pharmacoepidemiology (Elective course - course coordinator).
- 4) Design and analysis of experiments (Elective course – lecturer).
- 5) Methods and Procedures in Clinical Drug Development (Elective course – lecturer).
- 6) Regulatory aspects of Pharmacovigilance (Elective course – lecturer).
- 7) Tools in signal detection (Elective course – lecturer).
- 8) AI and Big Data in Drug Safety (Elective course – course coordinator).
- 9) Fundamentals of drug utilization research using real-world data (PhD course – course coordinator).
- 10) Fundamentals of Pharmacoepidemiology using multi-country data sources (PhD course – course coordinator).

• ORGANISATION OF SCIENTIFIC MEETINGS

2023 Organizing committee - International Society for Pharmacoepidemiology Mid-year meeting 2023 - Reykjavik, Iceland
2022 Organizing committee - International Society for Pharmacoepidemiology Mid-year meeting 2022 - Reykjavik, Iceland
2021 DRA Symposium on Data science tools in pharmaceutical research with emphasis on machine learning (ML) and artificial intelligence (AI) - Copenhagen, Denmark
2021 Chairman of the sessions “Rise of the machines: Big data analytics and machine learning in pharmacoepidemiology” and “Metabolic Syndromes and Pharmacoepidemiology” - International Society for Pharmacoepidemiology Mid-year meeting 2021
2019 - 2022 Chair of the organizing committee – Yearly seminar of the Metabolism and Inflammation Research Cluster (MIRC) Symposium - Copenhagen, Denmark

• INSTITUTIONAL RESPONSIBILITIES

External Institutional responsibilities:

2022 **Role:** Opponent PhD Thesis; **Thesis:** pharmacoepidemiological studies of rheumatoid arthritis – Methodological Considerations and Applications. **Place:** Karolinska Institutet

Institutional responsibilities at the University of Copenhagen:

2020-ongoing **Role:** Representative of the Pharmaceutical Data Science Committee; **Activities:** planning pharmaceutical data science courses at the Faculty of Health and Medical Sciences.
2020-ongoing **Role:** Chair of the Young Pharma Forum; **Activities:** support career development of young researcher at the Faculty of Health and Medical Sciences.
2019-ongoing **Role:** Core member of the Metabolism and Inflammation and Personalized medicine Research Clusters, **Activities:** promote the development of research pipeline in personalized medicine, metabolism, and inflammation using real-world data.

• REVIEWING ACTIVITIES

- 2022 Review Board member for grants sent the ZonMw ‘Open Competition Call 11’, a grant round intended for curiosity-driven scientific research within the field of Rational Pharmacotherapy - Dutch Research Council.
- 2017-ongoing Review Board member for more than 50 academic journals (e.g., Clinical Pharmacology and Therapeutics, Cardiovascular Drugs, Scientific Reports, Therapeutic Advances in Chronic Disease, Cephalalgia, Expert Opinion on Drug Safety, Frontiers in Artificial Intelligence, Drug Healthcare and Patient Safety, PLoS One, Renal Failure, and Pharmacoepidemiology and Drug Safety)
- 2018-ongoing Review Board member for abstracts submitted to conferences organized by the International Society for Pharmacoepidemiology

• MAJOR SCIENTIFIC COLLABORATIONS

I am currently collaborating on several granted research projects with Prof. Morten Andersen, the head of the Pharmacovigilance Research Center at the University of Copenhagen. At the Department of Drug Design and Pharmacology, I have strengthened my research collaborations with two key Research Clusters, “*Metabolism and Inflammation Research Cluster*” and “*Personalized Medicine Research Cluster*” led by Prof. Trond Ulven and Prof. Miriam Kolko (<https://pubmed.ncbi.nlm.nih.gov/32510245/>) with targeted research grants. Additionally, at the Department of Pharmacy, I have strengthened my collaboration with Assoc. Prof. *Christine Erikstrup Hallgreen*, the head of the Copenhagen Centre for Regulatory Science with a grant for developing an automatized infrastructure for retrieving data from regulatory documents. Finally, I have an ongoing EU-funded project with Assoc. Prof. *Julien Kirchgessner* from the University of Sorbonne for educational activities in Pharmacoepidemiology in Europe.

Other key research collaborators include:

- Prof. Christian Torp-Pedersen – University of Copenhagen, Department of Public Health, Clinical Professor.
- Anders Peter Hviid – Statens Serum Institut, Senior Researcher, Professor, Epidemiologisk Forskning / Afdeling for Epidemiologisk Forskning.

Research networks:

- >250 research collaborators affiliated with 160 different research institutions from 27 countries (source: Scopus).
- International Society of Pharmacoepidemiology – Special Interest Group in geriatric pharmacoepidemiology.
- NorPEN - a network of researchers with the purpose of facilitating research within the field of pharmacoepidemiology in the Nordic countries.

Consortia:

- Minerva consortium: a network of 35 research collaborators from several European countries involved in evidence generation from multi-countries pharmacoepidemiological studies

• INVITED SCIENTIFIC PRESENTATION AT NATIONAL AND INTERNATIONAL CONFERENCES

I have received more than 20 invitations for scientific presentations at National and International conferences. Selected invitations include:

- 1) National Conference of the Danish Society for Pharmacology (15th January 2020 in Odense, Denmark).
- 2) 18th World Congress of Basic and Clinical Pharmacology (August 2018 in Kyoto, Japan).
- 3) 2021 Mid-Year Meeting of the International Society for Pharmacoepidemiology (Online).
- 4) 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (March 2018, Göttingen, Germany).
- 5) 39th National Meeting of the Italian Society of Pharmacology (November 2019 in Florence, Italy).
- 6) 2021 Annual Meeting of the International Society for Pharmacoepidemiology (Online).
- 7) 2022 Annual Meeting of the International Society for Pharmacoepidemiology (Bella Center, Copenhagen, Denmark).
- 8) 2022 Annual Meeting of NorPEN, Tampere, Finland.
- 9) EuroDURG 2023, Bologna, Italy
- 10) ISPE mid-year meeting 2023, Reykjavik, Island

- **EARLY ACHIEVEMENTS TRACK-RECORD**

My early work (PhD) focused on investigating the association between molecular properties of beta-blockers and cardiorespiratory outcomes in patients with heart failure and chronic obstructive pulmonary disease using Danish administrative registers. An important achievement of this work was the discovery of a negative correlation between the use of beta-blockers with high beta-2 adrenoceptor selectivity and the risk of heart failure hospitalization due to the vicious negative link between bronchoconstriction, oxygen saturation, and heart failure contractility. The results of my PhD project have been pivotal to strengthening the recommendation in the European Society of Cardiology guidelines on the use of metoprolol rather than carvedilol in patients having both heart failure and chronic obstructive pulmonary disease (<https://pubmed.ncbi.nlm.nih.gov/29327802/>). On the paper published during my PhD was accompanied by an editorial paper in the official journal of the European Society of Cardiology and mentioned in other scientific journals such as ESC Heart Failure, BMJ, and, JACC: Heart Failure. I further investigated this topic using Italian and Danish administrative databases to unveil the association between molecular properties of beta-blocker and long-term outcomes focusing on clinically relevant subgroups identified using AI-driven models. This was a radically new approach for investigating the safety of beta-blockers as it used data on molecular properties from molecular pharmacology and cheminformatics in combination with data science methods while using administrative databases as data sources. During my postdoc at the University of Copenhagen, I focused on how to translate this approach to other data sources used in Pharmacovigilance such as spontaneous reports of adverse events while integrating artificial intelligence techniques from data science. The most important result was the preliminary discovery of being able to anticipate the detection of safety signals using the molecular properties of drugs such as affinity to off-target in spontaneous reporting databases for which I have pluriannual experience in management and analysis. The results of this research have also been published in in non-scientific journal aiming at lay communication of research findings such as BestPractice Nordic Online. Recently, to automatize the classification of identified safety signals as “not under evaluation by Regulatory Agency” among those identified with the new approach described above in collaboration with Ass. Prof. Christine Erikstrup Hallgreen, I started the development of an Artificial intelligence-guided infrastructure for real-time analytics of regulatory documents that received funds from the University of Copenhagen (please refer to the section on grants). My early scientific contribution is in line with my willingness of pursuing multidisciplinary research. I have always been a fervent partisan of the multidisciplinary approach in scientific investigations, and my current research interests are strongly driven by this motivation. This has been recognized at multiple levels, from the wide variety of nature of the journals I published into and the variety of journals soliciting me for papers (e.g., the use of machine learning in Pharmacoepidemiology by Frontiers in Pharmacology).

Awards as a student: 1) Best Communication Award, Italian Society of Pharmacology, Italy (in 2016); 2) Pharmacy student with the highest academic achievements in 2016, Second University of Naples, Italy; 3) best thesis in Pharmacy, Rotary international, Italy (2016).

- **CURRENT GRANTS**

Project Title	Funding source (founding ID)	Amount (Euros)	Period	My Role
Seed4EU+	4EU+	50000€	September 2023 – September 2024	Principal investigator (10% of the working time)
Pharmacometrics-based clustering for Pharmacoepidemiological risk stratification in real-world evidence for drugs with a narrow therapeutic index: a data science approach.	Helsefonden (20-B-0059)	47039€	March 2021 – September 2021	Principal investigator (10% of the working time) I have employed a postdoc (Hiie Soeorg) for a mini-project that aims at using pharmacometrics models from the scientific literature for pharmacological substantiation of

				safety signals identified using Danish administrative registers as data sources for drugs with a narrow therapeutic index.
Nordic COllaborative HEalth REgister Network for Covid-19 Epidemiology (Nordic COHERENCE)	Nordforsk (105670)	970470€	February 2021 – February 2023	Work package leader (10% of the working time) I am involved in a multi-country project (e.g., Denmark, Norway, Sweden, and Scotland) as work package leader for a project aiming at evaluating risk factors for severe Covid-19 (disease leading to hospitalization, intensive care, or fatal outcome), identifying vulnerable populations, and characterizing the disease course, also on long-term sequelae among survivors of severe Covid-19. My work package aims at using administrative data sources and machine-learning techniques for identifying pharmacological treatments that may represent risk factors for severe Covid-19 infections.
Regulatory Science focusing on the development of an infrastructure for real-time analytics of regulatory documents	Novo Nordisk A/S	268000€	May 2021 – May 2023	Co-Principal Investigator (10% of the working time). I have employed a postdoc (Mohnish Pandey) for this project.
Targeting GPCRs for treatment of fibrosis	Novo Nordisk A/S	6000000 DKK	January 2022 – December 2024	Work package leader (10% of the working time)
Development of an integrated 4EU+ Pharmacoepidemiology educational program	4EU+	13312€	January 2022 – May 2022	Co-Principal Investigator (5% of the working time).

Peer-reviewed publications ordered by year of publication
(2 publications have been omitted because errata of original articles)

First or Last authorship (*)	Title	Journal	Year	N.
*	Dong G, Kjærgaard NA, Shakibfar S, Sessa M. Ubrogapant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. <i>Expert Opin Drug Saf</i> 2023:1–12. https://doi.org/10.1080/14740338.2023.2177270 .	Expert Opinion on Drug Safety	2023	78
*	Wang W, Battini V, Carnovale C, Noordam R, van Dijk KW, Kragholm KH, et al. A novel approach for pharmacological substantiation of safety signals using plasma concentrations of medication and	Pharmacological research	2023	78

	administrative/healthcare databases: A case study using Danish registries for an FDA warning on lamotrigine. <i>Pharmacol Res</i> 2023;193:106811. https://doi.org/10.1016/j.phrs.2023.106811 .			
*	Battini V, Carnovale C, Clementi E, Sessa M. Ubrogепant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System. <i>Expert Opin Drug Saf</i> 2023:1–8. https://doi.org/10.1080/14740338.2023.2223958 .	Expert Opinion on Drug Safety	2023	77
*	Amiri D, Sessa M, Andersen M, Kolko M. Persistence and adherence with Latanoprost: A Danish register-based cohort study in older patients with glaucoma. <i>Acta Ophthalmol</i> 2023. https://doi.org/10.1111/aos.15715 .	Acta Ophthalmologica	2023	76
*	Al-Azzawi F, Mahmoud I, Haguinet F, Bate A, Sessa M. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data. <i>Drug Saf</i> 2023. https://doi.org/10.1007/s40264-023-01317-0 .	Drug Safety	2023	75
*	Breitenstein PS, Mahmoud I, Al-Azzawi F, Shakibfar S, Sessa M. A machine-learning guided method for predicting add-on and switch in secondary data sources: A case study on anti-seizure medications in Danish registries. <i>Front Pharmacol</i> 2022;13:954393. https://doi.org/10.3389/fphar.2022.954393 .	Frontiers in Pharmacology	2022	74
	Godtfredsen SJ, Kragholm KH, Leutscher P, Jørgensen SH, Christensen MK, Butt JH, Gislason G, Køber L, Fosbøl EL, Sessa M, Bhatt DL, Torp-Pedersen C, Pareek M. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. <i>Eur Heart J Acute Cardiovasc Care</i> . 2022 Sep 29;11(9):697-705. doi: 10.1093/ehjacc/zuac095. PMID: 35950769.	Eur Heart J Acute Cardiovasc Care	2022	73
	Ravaioli M, Germinario G, Dajti G, Sessa M, Vasuri F, Siniscalchi A, Morelli MC, Serenari M, Del Gaudio M, Zanfi C, Odaldi F, Bertuzzo VR, Maroni L, Laurenzi A, Cescon M. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial. <i>Am J Transplant</i> . 2022 Oct;22(10):2401-2408. doi: 10.1111/ajt.17115. Epub 2022 Jun 21. PMID: 35671067.	Am J Transplant	2022	72
*	Sessa M, Lai Q, Germinario G, Ravaioli M. Reply to: "Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations". <i>J Hepatol</i> . 2022 Aug;77(2):573-574. doi: 10.1016/j.jhep.2022.04.034. Epub 2022 May 7. PMID: 35537651.	J Hepatol	2022	71
	Aakjær M, Kristiansen SB, Pape K, Sessa M, Dalhoff KP, De Bruin ML, Andersen M. Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study. <i>Int J Epidemiol</i> . 2022 Oct 13;51(5):1656-1665. doi: 10.1093/ije/dyac071. PMID: 35472246; PMCID: PMC9558065.	Int J Epidemiol	2022	70

*	Pazzagli L, Liang D, Andersen M, Linder M, Khan AR, Sessa M . Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources. <i>Sci Rep</i> . 2022 Apr 15;12(1):6245. doi: 10.1038/s41598-022-10144-9. PMID: 35428827; PMCID: PMC9012860.	Sci Rep	2022	69
*	Soeorg H, Sverrisdóttir E, Andersen M, Lund TM, Sessa M . Artificial Neural Network vs. Pharmacometric Model for Population Prediction of Plasma Concentration in Real-World Data: A Case Study on Valproic Acid. <i>Clin Pharmacol Ther</i> . 2022 Jun;111(6):1278-1285. doi: 10.1002/cpt.2577. Epub 2022 Mar 25. PMID: 35263452.	Clin Pharmacol Ther	2022	68
*	Liang D, Sessa M . Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. <i>Expert Opin Drug Saf</i> . 2022 Sep;21(9):1205-1210. doi: 10.1080/14740338.2022.2049231. Epub 2022 Mar 10. PMID: 35236231.	Expert Opin Drug Saf	2022	67
	Abrate A, Sessa F, Sessa M , Campi R, Sebastianelli A, Varca V, Pavone C, Vella M, Bartoletti R, Ficarra V, Serni S, Brunocilla E, Gregori A, Trombetta C, Lissiani A, Terrone C, Gontero P, Schiavina R, Gacci M, Simonato A. Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma. <i>Clin Genitourin Cancer</i> . 2022 Aug;20(4):381-387. doi: 10.1016/j.clgc.2022.01.007. Epub 2022 Jan 13. PMID: 35125302.	Clin Genitourin Cancer	2022	66
*	Soeorg H, Sverrisdóttir E, Andersen M, Lund TM, Sessa M . The PHARMACOM-EPI Framework for Integrating Pharmacometric Modelling Into Pharmacoepidemiological Research Using Real-World Data: Application to Assess Death Associated With Valproate. <i>Clin Pharmacol Ther</i> . 2022 Apr;111(4):840-856. doi: 10.1002/cpt.2502. Epub 2021 Dec 27. PMID: 34860420.	Clin Pharmacol Ther	2022	65
	Odaldi F, Serenari M, Comai G, La Manna G, Bova R, Frascaroli G, Malvi D, Maroni L, Vasuri F, Germinario G, Baraldi O, Capelli I, Cuna V, Sangiorgi G, D'Errico A, Del Gaudio M, Bertuzzo VR, Zanfi C, Sessa M , Ravaioli M. The Relationship between Timing of Pretransplant Kidney Biopsy, Graft Loss, and Survival in Kidney Transplantation: An Italian Cohort Study. <i>Nephron</i> . 2022;146(1):22-31. doi: 10.1159/000518610. Epub 2021 Oct 27. PMID: 34818242.	Nephron	2022	64
	Ravaioli M, Lai Q, Sessa M , Ghinolfi D, Fallani G, Patrono D, Di Sandro S, Avolio A, Odaldi F, Bronzoni J, Tandoi F, De Carlis R, Pascale MM, Mennini G, Germinario G, Rossi M, Agnes S, De Carlis L, Cescon M, Romagnoli R, De Simone P. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy. <i>J Hepatol</i> . 2022 Mar;76(3):619-627. doi: 10.1016/j.jhep.2021.10.024. Epub 2021 Nov 10. PMID: 34774638.	J Hepatol	2022	63

*	Pazzagli L, Andersen M, Sessa M . Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: A simulation study. <i>Pharmacoepidemiol Drug Saf</i> . 2022 Jan;31(1):55-60. doi: 10.1002/pds.5366. Epub 2021 Oct 15. PMID: 34611960.	Pharmacoepidemiol Drug Saf	2022	62
*	Liang D, Gardella E, Kragholm K, Polcwiartek C, Sessa M . The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study. <i>J Card Fail</i> . 2022 Apr;28(4):630-638. doi: 10.1016/j.cardfail.2021.07.020. Epub 2021 Aug 24. PMID: 34438055.	J Card Fail	2022	61
	Ravaioli M, Piscaglia F, Cillo U, Brandi G, Sessa M , Germinario G, Golfieri R, Cappelli A, Morelli MC, Siniscalchi A, D'Errico A. Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. <i>Liver Cancer</i> . 2021 Jun 1:1-2.	Liver Cancer	2021	60
*	Liang D, Gardella E, Kragholm K, Polcwiartek C, Sessa M . The Relationship between Valproate Versus Lamotrigine/Levetiracetam Use and Prognosis in Patients with Epilepsy and Heart Failure: a Danish Register-Based Study. <i>Journal of Cardiac Failure</i> . Accepted 30/07/2021	Journal of Cardiac Failure	2021	59
*	Meaidi M, Støvring H, Rostgaard K, Torp-Pedersen C, Kragholm KH, Andersen M, Sessa M . Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources. <i>Eur J Clin Pharmacol</i> . 2021 Jul 10. doi: 10.1007/s00228-021-03188-9. Epub ahead of print. PMID: 34247270.	Eur J Clin Pharmacol	2021	58
*	Sessa M , Kragholm K, Hviid A, Andersen M. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines. <i>Expert Opin Drug Saf</i> . 2021 Jul 26:1-3. doi: 10.1080/14740338.2021.1955101. Epub ahead of print. PMID: 34264151.	Expert Opin Drug Saf	2021	57
	Kragholm K, Sessa M , Mulvad T, Andersen MP, Collatz-Christensen H, Blomberg SN, Lippert F, Mikkelsen S, Leutscher P, Melgaard D, Torp-Pedersen C, Kristensen SR, Larsen TB, Sogaard P. Thrombocytopenia after COVID-19 vaccination. <i>J Autoimmun</i> . 2021 Jul 27;123:102712. doi: 10.1016/j.jaut.2021.102712. Epub ahead of print. PMID: 34332437; PMCID: PMC8313538.	J Autoimmun	2021	56
*	Sessa M , Andersen M. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database. <i>BioDrugs</i> . 2021 Jan 30. doi: 10.1007/s40259-021-00469-8.	BioDrugs	2021	55
*	Sessa M , Liang D, Khan AR, Kulahci M, Andersen M. Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 2-Comparison of the Performance of Artificial Intelligence and Traditional Pharmacoepidemiological Techniques. <i>Front Pharmacol</i> . 2021 Jan 14;11:568659. doi:	Front Pharmacol	2021	54

	10.3389/fphar.2020.568659. PMID: 33519433; PMCID: PMC7841344.			
	Jakobsen LH, Callréus T, Sessa M , Jerkeman M, Andersen M, El-Galaly TC. Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma. <i>Pharmacoepidemiol Drug Saf</i> . 2021 Jan 12. doi: 10.1002/pds.5195. Epub ahead of print. PMID: 33432654.	Pharmacoepidemiol Drug Saf	2021	53
	Hagengaard L, Polcwiartek C, Andersen MP, Sessa M , Krogager ML, Gislason G, Schou M, Torp-Pedersen C, Søggaard P, Kragholm KH. Incident atrial fibrillation and risk of psychoactive drug redemptions and psychiatric hospital contacts: a Danish Nationwide Register-based Follow-up Study. <i>Eur Heart J Qual Care Clin Outcomes</i> . 2021 Jan 25;7(1):76-82. doi: 10.1093/ehjqcco/qcaa048. PMID: 32502251.	Eur Heart J Qual Care Clin Outcomes	2021	52
	Cito G, Coccia ME, Fucci R, Picone R, Cocci A, Sessa M , Sessa F, Rizzello F, Micelli E, Trotta M, Badolato L, Campi R, Criscuoli L, Serni S, Carini M, Natali A. Hepatitis B Surface Antigen Seropositive Men in Serodiscordant Couples: Effects on the Assisted Reproductive Outcomes. <i>World J Mens Health</i> . 2021 Jan;39(1):99-106. doi: 10.5534/wjmh.190121. Epub 2019 Dec 17. PMID: 32009315; PMCID: PMC7752521.	World J Mens Health	2021	51
*	Sessa M , Khan AR, Liang D, Andersen M, Kulahci M. Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1-Overview of Knowledge Discovery Techniques in Artificial Intelligence. <i>Front Pharmacol</i> . 2020 Jul 16;11:1028. doi: 10.3389/fphar.2020.01028. PMID: 32765261; PMCID: PMC7378532.	Front Pharmacol	2020	50
*	Hauser AS, Kooistra AJ, Sverrisdóttir E, Sessa M . Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance. <i>Expert Opin Drug Saf</i> . 2020 Aug;19(8):961-968. doi: 10.1080/14740338.2020.1780208. Epub 2020 Jun 25. PMID: 32510245.	Expert Opin Drug Saf	2020	49
*	Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirgulyev S, Al-Karagholi MA, Amin FM, Sessa M . A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. <i>Expert Opin Drug Saf</i> . 2020 Dec 29;1-8. doi:10.1080/14740338.2021.1866537. Epub ahead of print. PMID: 33337920.	Expert Opin Drug Saf	2020	48
*	Hashimi H, Andersen M, Sessa M . Predictors of quetiapine extended-release formulation add-on in older patients exposed to antidepressant drugs: A Danish register-based cohort study. <i>Int J Geriatr Psychiatry</i> . 2020 May 19. doi: 10.1002/gps.5351. Epub ahead of print. PMID: 32428273.	Int J Geriatr Psychiatry	2020	47
	Abrate A, Sessa F, Campi R, Preto M, Olivero A, Varca V, Benelli A, Sessa M , Sebastianelli A, Pavone C, Serretta V, Vella M, Brunocilla E, Serni S, Trombetta C, Terrone C, Gregori A, Lissiani A, Gontero P, Schiavina R, Gacci M, Simonato A. Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m ² : A	Urol Oncol.	2020	46

	multicenter study. <i>Urol Oncol.</i> 2020 Jun;38(6):601.e11-601.e16. doi: 10.1016/j.urolonc.2020.03.005. Epub 2020 Apr 6. PMID: 32273050.			
*	Sessa M , Mascolo A, Dalhoff KP, Andersen M. The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine. <i>Expert Opin Drug Saf.</i> 2020 Mar;19(3):349-357. doi: 10.1080/14740338.2020.1711882. Epub 2020 Jan 6. PMID: 31903798.	Expert Opin Drug Saf	2020	45
*	Sessa M , Rasmussen DB, Jensen MT, Kragholm K, Torp-Pedersen C, Andersen M. Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. <i>Am J Cardiol.</i> 2020 Apr 1;125(7):1069-1076. doi: 10.1016/j.amjcard.2019.12.048. Epub 2020 Jan 9. PMID: 32000982.	Am J Cardiol	2020	44
*	Sessa M , Mascolo A, Rasmussen DB, Kragholm K, Jensen MT, Sportiello L, Rafaniello C, Tari GM, Pagliaro C, Andersen M, Rossi F, Capuano A. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. <i>Sci Rep.</i> 2019 Aug 7;9(1):11465. doi: 10.1038/s41598-019-47967-y. PubMed PMID: 31391573; PubMed Central PMCID: PMC6685956.	Sci Rep	2019	43
	Esposito R, Spaziano G, Giannattasio D, Ferrigno F, Liparulo A, Rossi A, Roviezzo F, Sessa M , Falciani M, Berrino L, Polverino M, Polverino F, D'Agostino B. Montelukast improves symptoms and lung function in asthmatic women compared with men. <i>Front Pharmacol</i> 2019; 10: 1094.	Front Pharmacol	2019	42
	Mascolo A, Urbanek K, De Angelis A, Sessa M , Scavone C, Berrino L, Rosano GMC, Capuano A, Rossi F. Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation? <i>Heart Fail Rev.</i> 2019 Aug 2. doi: 10.1007/s10741-019-09837-7. [Epub ahead of print] Review. PubMed PMID: 31375968.	Heart Fail Rev	2019	41
	Sebastianelli A, Spatafora P, Frizzi J, Saleh O, Sessa M , De Nunzio C, Tubaro A, Vignozzi L, Maggi M, Serni S, McVary KT, Kaplan SA, Gravas S, Chapple C, Gacci M. Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. <i>J Clin Med.</i> 2019 Jul 29;8(8). pii: E1126. doi: 10.3390/jcm8081126. PubMed PMID: 31362410; PubMed Central PMCID: PMC6723816.	J Clin Med	2019	40
	Hagengaard L, Sogaard P, Espersen M, Sessa M , Lund PE, Krogager ML, Torp-Pedersen C, Kragholm KH, Polcwiartek C. Association Between Serum Potassium Levels and Short-Term Mortality in Patients With Atrial Fibrillation or Flutter Co-treated With Diuretics and Rate- or Rhythm-Controlling Drugs. <i>Eur Heart J Cardiovasc Pharmacother.</i> 2019 Jul 2. pii: pvz024. doi: 10.1093/ehjcvp/pvz024. [Epub ahead of print] PubMed PMID: 31263883.	Eur Heart J Cardiovasc Pharmacother	2019	39
	Mascolo A, Ruggiero R, Sessa M , Scavone C, Sportiello L, Rafaniello C, Rossi F, Capuano A.	Front Pharmacol	2019	38

	Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System. <i>Front Pharmacol.</i> 2019 Apr 30;10:425. doi: 10.3389/fphar.2019.00425. eCollection 2019. PubMed PMID: 31114497; PubMed Central PMCID: PMC6503045.			
	Andersen MP, Valeri L, Starkopf L, Mortensen RN, Sessa M , Kragholm KH, Vardinghus-Nielsen H, Bøggild H, Lange T, Torp-Pedersen C. The Mediating Effect of Pupils' Physical Fitness on the Relationship Between Family Socioeconomic Status and Academic Achievement in a Danish School Cohort. <i>Sports Med.</i> 2019 Aug;49(8):1291-1301. doi: 10.1007/s40279-019-01117-6. PubMed PMID: 3111445.	Sports Med	2019	37
*	Sessa M , Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®). <i>Sci Rep.</i> 2019 May 10;9(1):7236. doi: 10.1038/s41598-019-43715-4. PubMed PMID: 31076635; PubMed Central PMCID: PMC6510783.	Sci Rep	2019	36
	Abrate A, Sessa F, Sebastianelli A, Preto M, Olivero A, Varca V, Benelli A, Campi R, Sessa M , Pavone C, Serretta V, Vella M, Brunocilla E, Serni S, Trombetta C, Terrone C, Gregori A, Lissiani A, Gontero P, Schiavina R, Gacci M, Simonato A. Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study. <i>BJU Int.</i> 2019 Feb 3. doi: 10.1111/bju.14697. [Epub ahead of print] PubMed PMID: 30712313.	BJU Int	2019	35
	Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M , Capuano A, Torp-Pedersen C, Gislason G, Lange P, Jensen MT. Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. <i>Eur Heart J.</i> 2019 Jan 4. doi: 10.1093/ehjqcco/qcy063. [Epub ahead of print] PubMed PMID: 30608575.	Eur Heart J	2019	34
*	Sessa M , Mascolo A, Scavone C, Perone I, Di Giorgio A, Tari M, Fucile A, De Angelis A, Rasmussen DB, Jensen MT, Kragholm K, Rossi F, Capuano A, Sportiello L. Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β 1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. <i>Front Pharmacol.</i> 2018 Oct 25;9:1212. doi: 10.3389/fphar.2018.01212. eCollection 2018. PubMed PMID: 30459608; PubMed Central PMCID: PMC6232895.	Front Pharmacol	2018	33
	Vignolini G, Sessa F, Greco I, Cito G, Vanacore D, Cocci A, Sessa M , Grandi V, Pili A, Giancane S, Gacci M, Sebastianelli A, Li Marzi V, Breda A, Campi R, Serni S. Intraoperative assessment of ureteral and graft reperfusion during robotic kidney transplantation with indocyanine green fluorescence videography. <i>Minerva Urol Nefrol.</i> 2019 Feb;71(1):79-84. doi: 10.23736/S0393-2249.18.03278-2. Epub 2018 Nov 7. PubMed PMID: 30421596.	Minerva Urol Nefrol	2018	32

	Guerriero F, Orlando V, Monetti VM, Colaccio FM, Sessa M , Scavone C, Capuano A, Menditto E. Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy. <i>Ther Clin Risk Manag</i> . 2018 Oct 8;14:1907-1914. doi: 10.2147/TCRM.S171346. eCollection 2018. PubMed PMID: 30349269; PubMed Central PMCID: PMC6183659.	Ther Clin Risk Manag	2018	31
	Scavone C, Sessa M , Clementi E, Corrao G, Leone R, Mugelli A, Rossi F, Spina E, Capuano A. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. <i>BioDrugs</i> . 2018 Dec;32(6):607-617. doi: 10.1007/s40259-018-0313-2. PubMed PMID: 30341487; PubMed Central PMCID: PMC6290713.	BioDrugs	2018	30
*	Sessa M , Mascolo A, D'Agostino B, Casciotta A, D'Agostino V, Michele F, Polverino M, Spaziano G, Andersen MP, Kragholm K, Rossi F, Torp-Pedersen C, Capuano A. Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study. <i>Front Pharmacol</i> . 2018 Aug 2;9:844. doi: 10.3389/fphar.2018.00844. eCollection 2018. PubMed PMID: 30116192; PubMed Central PMCID: PMC6083053.	Front Pharmacol	2018	29
*	Sessa M , Bernardi FF, Vitale A, Schiavone B, Gritti G, Mascolo A, Bertini M, Scavone C, Sportiello L, Rossi F, Capuano A. Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system. <i>J Clin Pharm Ther</i> . 2018 Dec;43(6):867-876. doi: 10.1111/jcpt.12744. Epub 2018 Jul 16. PubMed PMID: 30014479.	J Clin Pharm Ther	2018	28
*	Sessa M , di Mauro G, Mascolo A, Rafaniello C, Sportiello L, Scavone C, Capuano A. Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors. <i>Front Pharmacol</i> . 2018 Jun 12;9:611. doi: 10.3389/fphar.2018.00611. eCollection 2018. PubMed PMID: 29946258; PubMed Central PMCID: PMC6006791.	Front Pharmacol	2018	27
	Scavone C, Sessa M , Clementi E, Rossi F, Capuano A. Italian Immunization Goals: A Political or Scientific Heated Debate? <i>Front Pharmacol</i> . 2018 May 30;9:574. doi: 10.3389/fphar.2018.00574. eCollection 2018. PubMed PMID: 29899702; PubMed Central PMCID: PMC5989663.	Front Pharmacol	2018	26
	Grandi V, Sessa M , Pisano L, Rossi R, Galvan A, Gattai R, Mori M, Tiradritti L, Bacci S, Zuccati G, Cappugi P, Pimpinelli N. Photodynamic therapy with topical photosensitizers in mucosal and semimucosal areas: Review from a dermatologic perspective. <i>Photodiagnosis Photodyn Ther</i> . 2018 Sep;23:119-131.	Photodiagnosis Photodyn Ther	2018	25

	doi: 10.1016/j.pdpdt.2018.04.005. Epub 2018 Apr 15. Review. PubMed PMID: 29669264.			
*	Sessa M , Rafaniello C, Scavone C, Mascolo A, di Mauro G, Fucile A, Rossi F, Sportiello L, Capuano A. Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? <i>Expert Opin Drug Saf.</i> 2018 May;17(5):457-465. doi: 10.1080/14740338.2018.1458837. Epub 2018 Apr 5. PubMed PMID: 29619841.	Expert Opin Drug Saf	2018	24
	Grandi V, Bacci S, Corsi A, Sessa M , Puliti E, Murciano N, Scavone F, Cappugi P, Pimpinelli N. ALA-PDT exerts beneficial effects on chronic venous ulcers by inducing changes in inflammatory microenvironment, especially through increased TGF-beta release: A pilot clinical and translational study. <i>Photodiagnosis Photodyn Ther.</i> 2018 Mar;21:252-256. doi: 10.1016/j.pdpdt.2017.12.012. Epub 2017 Dec 22. PubMed PMID: 29277361.	Photodiagnosis Photodyn Ther	2018	23
*	Sessa M , Mascolo A, Mortensen RN, Andersen MP, Rosano GMC, Capuano A, Rossi F, Gislason G, Enghusen-Poulsen H, Torp-Pedersen C. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. <i>Eur J Heart Fail.</i> 2018 Mar;20(3):548-556. doi: 10.1002/ejhf.1045. Epub 2017 Nov 20. PubMed PMID: 29159953.	Eur J Heart Fail	2018	22
	Rafaniello C & Sessa M , Bernardi FF, Pozzi M, Cheli S, Cattaneo D, Baldelli S, Molteni M, Bernardini R, Rossi F, Clementi E, Bravaccio C, Radice S, Capuano A. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. <i>Pharmacogenomics J.</i> 2018 May 22;18(3):422-430. doi: 10.1038/tpj.2017.38. Epub 2017 Jul 18. PubMed PMID: 28719598.	Pharmacogenomics J	2018	21
*	Sessa M , Rossi C, Mascolo A, Scafuro A, Ruggiero R, Di Mauro G, Cappabianca S, Grassi R, Sportiello L, Rafaniello C. Contribution of Italian clinical research for contrast media-induced nonrenal adverse drug reactions over the last three decades: A systematic review. <i>J Pharmacol Pharmacother.</i> 2018 Sep;131(9):131-146. doi: 10.4103/jpp.JPP_92_18	J Pharmacol Pharmacother	2018	20
*	Sessa M , Rossi C, Mascolo A, Scavone C, di Mauro G, Grassi R, Sportiello L, Cappabianca S, Rafaniello C. Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review. <i>Ther Clin Risk Manag.</i> 2017 Oct 24;13:1463-1478. doi: 10.2147/TCRM.S144418. eCollection 2017. Review. PubMed PMID: 29123405; PubMed Central PMCID: PMC5661489.	Ther Clin Risk Manag	2017	19
	Scavone C, Sportiello L, Sullo MG, Ferrajolo C, Ruggiero R, Sessa M , Berrino PM, di Mauro G, Berrino L, Rossi F, Rafaniello C, Capuano A; BIO-Cam Group. Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. <i>Front Pharmacol.</i> 2017 Sep 6;8:607. doi: 10.3389/fphar.2017.00607. eCollection 2017. PubMed	Front Pharmacol	2017	18

	PMID: 28932193; PubMed Central PMCID: PMC5592230.			
	Andersen MP, Starkopf L, Sessa M , Mortensen RN, Vardinghus-Nielsen H, Bøggild H, Lange T, Torp-Pedersen C. The indirect and direct pathways between physical fitness and academic achievement on commencement in post-compulsory education in a historical cohort of Danish school youth. BMC Public Health. 2017 Sep 11;17(1):699. doi: 10.1186/s12889-017-4712-y. Erratum in: BMC Public Health. 2017 Sep 25;17(1):742. PubMed PMID: 28893221; PubMed Central PMCID: PMC5594547.	BMC Public Health	2017	17
	Mascolo A, Scavone C, Sessa M , di Mauro G, Cimmaruta D, Orlando V, Rossi F, Sportiello L, Capuano A. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacol Res. 2017 Sep;123:122-129. doi: 10.1016/j.phrs.2017.07.005. Epub 2017 Jul 8. Review. PubMed PMID: 28694146.	Pharmacol Res	2017	16
*	Sessa M , Sportiello L, Mascolo A, Scavone C, Gallipoli S, di Mauro G, Cimmaruta D, Rafaniello C, Capuano A. Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions. Front Pharmacol. 2017 May 26;8:305. doi: 10.3389/fphar.2017.00305. eCollection 2017. PubMed PMID: 28603499; PubMed Central PMCID: PMC5445158.	Front Pharmacol	2017	15
	Grandi V, Milanesi N, Sessa M , Gola M, Cappugi P, Pimpinelli N. Efficacy and safety of S--acyl glutathione 2% cream vs. placebo against UVB--induced erythema: a randomized, double--blinded clinical trial. G Ital Dermatol Venereol. 2017 Apr 11. doi: 10.23736/S0392-0488.17.05603-6. [Epub ahead of print] PubMed PMID: 28399620.	G Ital Dermatol Venereol	2017	14
	Pileri A, Agostinelli C, Sessa M , Quagliano P, Santucci M, Tomasini C, Grandi V, Fava P, Astrua C, Righi S, Patrizi A, Pileri SA, Pimpinelli N. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch. 2017 May;470(5):575-582. doi: 10.1007/s00428-017-2107-1. Epub 2017 Mar 20. PubMed PMID: 28321511.	Virchows Arch	2017	13
	Minervini A, Campi R, Sessa F, Derweesh I, Kaouk JH, Mari A, Rha KH, Sessa M , Volpe A, Carini M, Uzzo RG. Positive surgical margins and local recurrence after simple enucleation and standard partial nephrectomy for malignant renal tumors: systematic review of the literature and meta-analysis of prevalence. Minerva Urol Nefrol. 2017 Dec;69(6):523-538. doi: 10.23736/S0393-2249.17.02864-8. Epub 2017 Jan 26. Review. PubMed PMID: 28124871.	Minerva Urol Nefrol	2017	12
	Campi R, Minervini A, Mari A, Hatzichristodoulou G, Sessa F, Lapini A, Sessa M , Gschwend JE, Serni S, Roscigno M, Carini M. Anatomical templates of lymph node dissection for upper tract urothelial carcinoma: a systematic review of the literature. Expert Rev Anticancer Ther. 2017 Mar;17(3):235-246. doi:	Expert Rev Anticancer Ther	2017	11

	10.1080/14737140.2017.1285232. Epub 2017 Feb 6. Review. PubMed PMID: 28103449.			
	Mascolo A & Sessa M , Scavone C, De Angelis A, Vitale C, Berrino L, Rossi F, Rosano G, Capuano A. New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases. <i>Int J Cardiol.</i> 2017 Jan 15;227:734-742. doi: 10.1016/j.ijcard.2016.10.069. Epub 2016 Oct 27. Review. PubMed PMID: 27823897.	Int J Cardiol	2017	10
*	Sessa M , Rafaniello C, Sportiello L, Mascolo A, Scavone C, Maccariello A, Iannaccone T, Fabrazzo M, Berrino L, Rossi F, Capuano A. Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. <i>Expert Opin Drug Saf.</i> 2016 Dec;15(sup2):9-15. PubMed PMID: 27875917.	Expert Opin Drug Saf	2016	9
	Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M , Rossi F, Capuano A. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). <i>Expert Opin Drug Saf.</i> 2016 Dec;15(sup2):85-100. Review. PubMed PMID: 27875916.	Expert Opin Drug Saf	2016	8
*	Sessa M , Rossi C, Rafaniello C, Mascolo A, Cimmaruta D, Scavone C, Fiorentino S, Grassi E, Reginelli A, Rotondo A, Sportiello L. Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions. <i>Expert Opin Drug Saf.</i> 2016 Dec;15(sup2):51-59. PubMed PMID: 27855534.	Expert Opin Drug Saf	2016	7
*	Sessa M , Mascolo A, Andersen MP, Rosano G, Rossi F, Capuano A, Torp-Pedersen C. Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. <i>PLoS One.</i> 2016 Jul 28;11(7):e0160337. doi: 10.1371/journal.pone.0160337. eCollection 2016. PubMed PMID: 27467520; PubMed Central PMCID: PMC4965154.	PLoS One	2016	6
*	Sessa M , Sullo MG, Mascolo A, Cimmaruta D, Romano F, Puca RV, Capuano A, Rossi F, Schiavo AL. A case of figurate urticaria by etanercept. <i>J Pharmacol Pharmacother.</i> 2016 Apr-Jun;7(2):106-8. doi: 10.4103/0976-500X.184777. PubMed PMID: 27440958; PubMed Central PMCID: PMC4936077.	J Pharmacol Pharmacother	2016	5
	Mascolo A, Rafaniello C, Sportiello L, Sessa M , Cimmaruta D, Rossi F, Capuano A. Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases. <i>Drug Saf.</i> 2016 May;39(5):401-7. doi: 10.1007/s40264-016-0399-8. Review. PubMed PMID: 26873369.	Drug Saf	2016	4
	Rafaniello C, Ferrajolo C, Sullo MG, Sessa M , Sportiello L, Balzano A, Manguso F, Aiezza ML, Rossi F, Scarpignato C, Capuano A. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. <i>Pharmacol Res.</i> 2016 Feb;104:108-14. doi: 10.1016/j.phrs.2015.12.026. Epub 2015 Dec 29. PubMed PMID: 26739516.	Pharmacol Res	2015	3

*	<p>Sessa M, Rossi C, Mascolo A, Grassi E, Fiorentino S, Scavone C, Reginelli A, Rotondo A, Sportiello L. Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance. <i>Expert Opin Drug Saf.</i> 2015;14(9):1341-51. doi: 10.1517/14740338.2015.1067301. Epub 2015 Jul 11. PubMed PMID: 26156557.</p>	Expert Opin Drug Saf	2015	2
	<p>Parretta E, Rafaniello C, Magro L, Coggiola Pittoni A, Sportiello L, Ferrajolo C, Mascolo A, Sessa M, Rossi F, Capuano A. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. <i>Expert Opin Drug Saf.</i> 2014 Sep;13 Suppl 1:S21-9. doi: 10.1517/14740338.2014.939582. PubMed PMID: 25171156.</p>	Expert Opin Drug Saf	2014	1